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Abstract DAYAS is a new two-part rating scale that
assesses: (1) ADHD and ODD symptoms (externalising
symptom ratings) and (2) symptomatology potentially
related to ADHD medication (potentially medication-rela-
ted symptoms) in real-world settings at different time
periods throughout a normal school day. Data from a proof-
of-concept study and two observational trials (Medikinet

retard [methylphenidate] and the Equasym XL
 [methyl-
phenidate] OBSEER study) evaluated: (1) validity of
weekly externalising symptom ratings using DAYAS, in
place of daily ratings; (2) reliability and internal consis-
tency of DAYAS ratings for externalising symptoms and
potentially medication-related symptoms; and (3) conver-
gent and divergent validity of the externalising symptom
ratings with existing validated scales. From the proof-of-
concept study, daily scores by period of day and during the
whole day correlated strongly with equivalent weekly
scores (r = 0.83–0.92). Internal consistency of externalis-
ing symptom rating scales calculated from pooled data
were acceptable or good by period of day (Cronbach’s
alpha = 0.68–0.90) and very high for whole day scores
(Cronbach’s alpha = 0.88–0.95). Internal consistency
of the rating scale for potentially medication-related
symptoms was also good for both teacher and parent rat-
ings. From OBSEER data, correlations between FBB-
ADHD total symptom scores and ratings on both parent
and teacher versions of DAYAS were high (r = 0.73 and
r = 0.84, respectively). Correlations between DAYAS and
SDQ were highest for the SDQ subscales hyperactivity and
conduct problems and substantially lower for pro-social
behaviour, peers and emotional problems. The DAYAS
rating scale had good internal consistency, and DAYAS
scores correlated well with existing validated scales and the
SDQ subscales hyperactivity and conduct problems.
Weekly DAYAS scores (whole day and by period of day)
could be considered a suitable replacement for daily
assessment scores.
Keywords ADHD  Parent report  Teacher report 
Screening instrument  Oppositional deﬁant disorder
Introduction
Attention deﬁcit hyperactivity disorder (ADHD) affects
over 5% of children worldwide and is the most commonly
diagnosed childhood neurobehavioural disorder [19].
Treatments for ADHD include stimulants, such as meth-
ylphenidate (MPH), which provide a rapid and dramatic
improvement of both behaviour and ADHD symptoms in
affected children [1]. However, MPH is quickly metabo-
lised to an inactive form, with a half-life in the body of
2–4 h and, therefore, a short duration of action [15]. Thus,
MPH needs to be taken repeatedly throughout the day in
order to maintain efﬁcacy, and this can lead to adherence
issues and additional complications if the drug needs to be
taken during school hours [16]. Long-acting formulations
of MPH combining both immediate release (IR) and
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DOI 10.1007/s00787-011-0206-0extended release (ER) components are now available that
avoid the need for additional doses during the day, while
still maintaining a rapid onset of therapeutic effect [13, 18].
Several well-designed and evaluated rating scales to
assess ADHD symptoms as perceived by parents or teachers
exist and have been used both in research assessing the
effects of pharmacotherapy or psychotherapy (e.g. Multisite
Treatment Study of ADHD [MTA] [17]) and in clinical
practice. Well-known examples of such scales include the
SNAP Checklist (Swanson) [21], ADHD rating scale [11],
Conners’ rating scales [3] and FBB-ADHD (Fre-
mdbeurteilungsbogen fu ¨r hyperkinetische Sto ¨rungen), a
German rating scale based on the International Classiﬁca-
tion of Disease, 10th revision (ICD-10) and Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition (DSM-
IV) [2, 12]. However, these rating scales assess ADHD
symptoms globally, usually over several weeks, and do not
distinguish between symptoms during different periods of
the day or in different situations. They cannot, therefore,
take account ofthe fact that ADHD symptoms may ﬂuctuate
throughout the day and even from one situation to another.
With the development of ER preparations with different
durations of action, rating scales that can assess ADHD
symptoms at different periods of the day, and thus assess the
duration of the action, are required. This is becoming
increasinglyimportanttobothresearchandclinicalpractice.
Previous attempts to assess the duration of action of a
givenpreparation,ortocomparedifferentpreparations,have
involved laboratory school or classroom analogue studies.
Patients were observed every 2–3 h while doing maths tests
and assessed with the Swanson, Kotkin, Agler, M-Flynn and
Pelham (SKAMP) rating scale [8, 22], designed speciﬁcally
to measure classroom aspects of ADHD. However, these
studies assess behaviour and medication effects in arbitrary
laboratory situations, which may not accurately reﬂect real-
world settings. Laboratory assessments are also very time-
consuming, making them impractical for large-scale
assessment of medication or assessment of the duration of
action in an individual titration procedure as is necessary at
the start of the treatment.
There is, therefore, a need for an easy-to-administer
instrument that could be used to assess ADHD symptoms
over different periods during a normal school day. Such an
instrument would need to be sensitive to change and able to
assess both treatment effects of medication and the dura-
tion of these effects; the most frequent side effects of
medication would also need to be assessed. In order to
cover a normal school day, both parent and teacher ratings
need to be included.
The Day Proﬁle of ADHD Symptoms (DAYAS) is a
translation of the German ADHS-Tagesproﬁlbogen [5]
(Supplementary material). DAYAS assesses the daily
proﬁle of ADHD and other externalising symptoms from
early morning until bedtime. DAYAS also incorporates an
evaluation of oppositional deﬁant disorder (ODD), the
most common coexisting behavioural problem in children
with ADHD. A teacher version of the questionnaire (DA-
YAS-T) considers the ﬁrst and second part of the morning
at school (in Germany, children usually attend school only
in the morning). This complements the parent version
(DAYAS-P), which covers the remaining four daily peri-
ods: early morning (before school), early afternoon until
4.00 pm, late afternoon until 7.00 pm and evening. The
rating scale evaluates six items: (1) hyperactivity, (2)
inattention, (3) impulsivity, (4) oppositional behaviour, (5)
aggressive behaviour and temper tantrums and (6) a global
rating of problem behaviour. A subscale, ADHD symptoms,
is comprised of items 1–3, and items 4 and 5 are combined
into a second subscale, ODD symptoms. For each period,
parents and teachers rate each item on a four-point scale
using the following values: 0 = not at all; 1 = just a little;
2 = pretty much; 3 = very much. The total score is the sum
of the six item scores per time period divided by the number
of items. Ratings are intended to reﬂect the behaviour of the
child at the different time periods of the day.
The second part of both DAYAS-P and DAYAS-T
assesses potential adverse effects of pharmacotherapy in 11
items and 9 items, respectively. These items were adapted
from the Pittsburgh Side-Effects Rating, as previously used
in the MTA [4, 17]. Pharmacotherapy-related items were
assessed not for each period of the day but for the whole
observation time (usually the last week).
The aims of this post hoc analysis are to assess:
1. the validity of weekly externalising symptom ratings
using DAYAS in place of daily ratings;
2. the internal consistency of the DAYAS externalising
symptom ratings and the ratings of potentially medi-
cation-related symptoms; and
3. the convergent and divergent validity of the external-
ising symptom ratings by analysing correlations with
other rating scales of ADHD, ODD and emotional
problems.
Methods
Participants and measures
Study 1: Proof-of-concept study, daily versus weekly
ratings with DAYAS and convergent validity
In a pilot study [23], 27 children were recruited (mean
age = 9.8 years, standard deviation [SD] = 1.4; 21 males;
59% receiving medication for ADHD) from an outpatient
unit with a diagnosis of ADHD (ICD-10 diagnoses: F90.0,
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12370%; F90.1, 26%; F90.9, 4%). Telephone assessment was
used to evaluate validity and reliability of the parent and
teacher rating scales (DAYAS-P/-T) for daily or weekly
evaluation of ADHD and ODD core symptoms (external-
ising symptoms). The study also examined whether daily
assessments of externalising symptoms could be replaced
by weekly ratings. A weekly rating of externalising
symptoms was collected for both DAYAS-P and DAYAS-
T in Week 1 and Week 2. Additionally, during Week 2,
daily ratings from Monday to Friday were collected. Par-
ents and teachers were also asked to rate ADHD and ODD
symptoms, according to DSM-IV and ICD-10, using the
FBB-ADHD and FBB-ODD checklists [9, 12].
Study 2: Psychometrics (Medikinet
 retard observational
study)
The Medikinet
 retard observational study [7] recruited
children and adolescents aged 6–17 years with a diagnosis of
ADHDforwhomtitrationof,orchangeto,Medikinet
retard/
XL(long-actingMPHwith50%MPH-IR;Medice,Germany)
wasplannedandwhohadnocontraindicationstothistherapy.
Data for 467 patients were collected, and data from 447
patients were included in an intent-to-treat analysis. Primary
outcomemeasureswereADHDseverityandsideeffectsrated
by physicians and parents, both at the start of the medication
switchand4–6 weekslater.Ateachassessment,teachers and
parents were asked to complete the weekly DAYAS to eval-
uate behavioural problems and ADHD symptoms. Efﬁcacy
was also assessed by physicians using the clinical global
impression (CGI) severity scale (ADHD-CGI–S).
Study 3: Psychometrics (OBSEER study)
OBSEER (OBservation of Safety and Effectiveness of
Equasym XL
 in Routine care) [6] was an open-label,
prospective, non-controlled, observational post-marketing
surveillance study conducted in Germany in accordance
with local regulations and under the therapeutic respon-
sibility of the attending physicians; ethics or institutional
review board approval was not required for this study.
The study enrolled 852 patients aged 6–17 years and
evaluable data were obtained for 822 patients. Eligible
patients had a diagnosis of ADHD, were about to com-
mence treatment with Equasym XL
1 (modiﬁed-release
MPH formulation with 30% MPH-IR and 70% MPH-ER;
Shire Pharmaceuticals Ireland Limited, Ireland) and were
attending school. Exclusion criteria were the presence of
any of the contraindications listed in the summary of
product characteristics or a mental handicap. Assessments
were carried out at baseline, after 1–3 weeks of treatment
and after 6–12 weeks of treatment. At each assessment,
teachers and parents were asked to complete question-
naires (strengths and difﬁculties questionnaire [SDQ-P;
14, 20], FBB-ADHD and DAYAS) to evaluate behav-
ioural problems and ADHD symptoms. Efﬁcacy was
assessed by physicians using the CGI–S and improvement
scales (CGI–I).
Statistical analyses
Pearson correlations were calculated to assess the validity
of weekly DAYAS ratings compared with daily DAYAS
ratings and to assess the convergent validity of the DAYAS
scales with other rating scales of ADHD and ODD. Internal
consistency was assessed by calculating Cronbach’s alpha.
Additionally, part-whole corrected correlations were cal-
culated to assess the correlation between item scores and
scale scores. Stepwise regression analyses were conducted
to analyse the multiple correlations between the different
DAYAS scores and the FBB-ADHD scores.
Results
Assessing the validity of the weekly rating compared
with the daily rating, and convergent validity
of externalising symptom ratings: study 1 data
Correlations between mean daily ratings and weekly rat-
ings on the DAYAS total score from the proof-of-concept
study are shown in Table 1. As expected, mean daily rat-
ings from Week 2 showed higher correlation with the
weekly ratings for the same week (correlation range by
period: 0.83–0.92) than with the weekly ratings for Week 1
(correlation range by period: 0.56–0.76). Test–retest reli-
ability of weekly ratings between Week 1 and Week 2 gave
a correlation value of r = 0.69 for DAYAS-P total score
for the whole day (the sum of the four daily periods rated
by the parents) and r = 0.74 for DAYAS-T total score for
the whole day (the sum of both daily periods rated by the
teachers).
To assess convergent validity, correlations were calcu-
lated between the DAYAS total scores for the whole day
and ratings on the FBB-ADHD and FBB-ODD. The DA-
YAS-P ratings (total scores, whole day) gave a correlation
of r = 0.52 with the parent-rated FBB-ADHD total score
and r = 0.56 with the parent-rated FBB-ODD total score.
Thus, the DAYAS-P total score reﬂected both ADHD and
1 Equasym XL is the UK trade name, and is registered and marketed
by Shire in the following countries under the following trademarks:
Denmark, Equasym Depot; Finland, Equasym Retard; France,
Quasym LP; Germany, Equasym Retard; Ireland, Equasym XL;
Netherlands, Equasym XL; Norway, Equasym Depot; Sweden,
Equasym Depot; South Korea, Metadate CD; Mexico, Metadate
CD. Information correct at August 2011.
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123ODD symptoms. The DAYAS-T ratings (total scores,
whole day) correlated well (r = 0.85) with the teacher-
rated FBB-ADHD total score and to a lesser extent
(r = 0.37) with the teacher-rated FBB-ODD total score.
Thus, the DAYAS-T total score reﬂected ADHD symptoms
to a higher degree than ODD symptoms.
Assessment of internal consistency: pooled data
from studies 2 and 3
Internal consistency was initially analysed in the Mediki-
net
 retard observational study (study 2) and the OBSEER
(study 3) samples separately. Only minimal differences in
Cronbach’s alpha and in the part-whole correlations in the
two samples were found. A combined sample from the two
studies gave a total analysis population of 1,269 children
(81.1% boys) aged 6–17 years (mean [SD] 10.27 [2.50]).
All children were attending school (54.1% attended pri-
mary school; 30.5% attended secondary school [Hau-
ptschule, 10.2%; Realschule, 13.1%; Gymnasium, 7.2%]
and 6.4% attended special schools for children with
learning difﬁculties or behavioural problems). Children in
the combined sample were diagnosed as having: hyperki-
netic disorder (F90.0, 52.9%), hyperkinetic conduct disor-
der (F90.1, 36.0%) or a non-speciﬁed hyperkinetic disorder
(11.1%) according to ICD-10 criteria.
The internal consistencies (Cronbach’s alpha) of the
DAYAS-P and DAYAS-T externalising symptom scales
and the potentially medication-related symptoms scales in
the combined sample at baseline are given in Table 2.
Despite the fact that the externalising symptom scales
ODD, ADHD and Total include only a few items (two,
three and six items, respectively), the internal consistencies
were acceptable or good for both DAYAS-P and DAYAS-
T with a range of Cronbach’s alpha = 0.68–0.95. The
potentially medication-related symptoms scales (contain-
ing 9 or 11 items in DAYAS-T and DAYAS-P, respec-
tively) were also in an acceptable range (Cronbach’s
alpha = 0.73–0.81). Table 2 includes all parent ratings of
ADHD and ODD by period and also the total scores for all
four periods of the day (whole day parent), the equivalent
for both teacher-rated periods (whole day teacher) and the
combined parent and teacher ratings. Internal consistencies
of these whole day scores were very high (Cronbach’s
alpha = 0.88–0.95), with part-whole correlations of
r = 0.40 or higher. These correlations indicate that the
ratings of the different daily periods are quite homoge-
nous—i.e. that patients with high ratings in the morning
also have high ratings in the evening—and therefore have a
similar contribution to the total scores.
Figure 1 shows the day proﬁle of the parent and teacher
externalising symptoms ratings in the combined Mediki-
net
 retard observational study and the OBSEER sample,
excluding cases with missing values (n = 632 for ADHD
and n = 649 for ODD symptom scores). The total means
(i.e. means across all daily ratings) for ADHD and ODD
ratings and the corresponding 95% conﬁdence intervals are
shown as horizontal bars in Fig. 1.
The highest symptom ratings for both ADHD and ODD
were found in the late afternoon, while the lowest ratings
were found in the ﬁrst part of the school morning, possibly
reﬂecting the fact that many patients were already receiv-
ing medication at baseline, which may have its main effect
in the ﬁrst half of the school morning.
In the OBSEER study, correlations between the
assessments at the ﬁrst and the second visit on the subscale
ADHD (ODD subscale) were r = 0.51 (r = 0.52) for
parent ratings, early afternoon and r = 0.62 (r = 0.65) for
teacher ratings, ﬁrst half of the school morning, indicating
a moderate stability even during the medication switch.
Similar stability coefﬁcients were found for the Medikinet

retard observational study.
Assessment of convergent and divergent validity:
study 3 data
Using baseline data from the OBSEER study, bi variate
Pearson correlations were calculated to evaluate
Table 1 Pearson correlations
between daily ratings and
weekly ratings of externalising
symptoms on the DAYAS total
score, from a proof-of-concept
study [23]
DAYAS Day Proﬁle of ADHD
Symptoms, DAYAS-P parent-
rated DAYAS, DAYAS-T
teacher-rated DAYAS
Correlation of mean daily rating
in Week 2 with weekly rating
in Week 1 and range of correlations
(in parentheses)
Correlation of mean daily rating
in Week 2 with weekly rating
in Week 2 and range of correlations
(in parentheses)
Early morning (DAYAS-P) 0.56 (0.31–0.56) 0.92 (0.63–0.88)
First half of school morning
(DAYAS-T)
0.76 (0.32–0.76) 0.84 (0.40–0.81)
Second half of school morning
(DAYAS-T)
0.60 (0.30–0.63) 0.85 (0.55–0.75)
Early afternoon (DAYAS-P) 0.68 (0.40–0.53) 0.86 (0.27–0.86)
Late afternoon (DAYAS-P) 0.62 (0.37–0.57) 0.83 (0.44–0.77)
Evening (DAYAS-P) 0.62 (0.36–0.55) 0.86 (0.54–0.71)
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123convergent validity between DAYAS externalising scores
and ratings of ADHD symptoms and impairment as
assessed by parents and teachers with the FBB-ADHD. The
highest correlations for FBB-ADHD symptoms and FBB-
ADHD impairment ratings by parents were found with the
early afternoon and in late afternoon parent ratings on the
DAYAS scale (Table 3). However, teacher ratings on the
DAYAS scale also had substantial positive correlations
with the FBB-ADHD parent ratings. Similarly, the highest
correlations with the FBB-ADHD teacher ratings were
found for DAYAS-T, but substantial correlations with
DAYAS-P were also seen.
Stepwise regression analyses with the four DAYAS-P
ADHD scores (early morning, early afternoon, late after-
noon, evening) as predictors and parent-rated FBB-ADHD
total symptom scores as criterion (n = 640) indicated that
all parent-rated DAYAS ADHD scores had a signiﬁcant
contribution to the multiple correlation of R = 0.73; 53%
of the variance (corrected R
2) of the FBB-ADHD scores
could be explained by variation of the DAYAS-P ADHD
scores at the different phases across the day. Similar
stepwise regression analyses with the two DAYAS-T
ADHD scores (ﬁrst and second half of school morning) as
predictors and the teacher-rated FBB-ADHD total symp-
tom score as criterion (n = 516) revealed that both DA-
YAS-T ADHD scores had a signiﬁcant contribution to the
multiple correlation of R = 0.84; 70% of the variance
(corrected R
2) of the FBB-ADHD scores could be
explained by variation of the two teacher-rated ADHD
scores across the school morning.
Table 2 Internal consistencies
(Cronbach’s alpha) of DAYAS-
P/-T scales in the combined
study sample at baseline
ADHD attention deﬁcit
hyperactivity disorder, DAYAS
Day Proﬁle of ADHD
Symptoms, DAYAS-P parent-
rated DAYAS, DAYAS-T
teacher-rated DAYAS, ODD
oppositional deﬁant disorder,
PMRS potentially medication-
related symptoms
Time N Items Cronbach’s
alpha
Part-whole correlations
range
Parent rating (DAYAS-P)
Early morning Total 1,074 6 0.88 0.64 0.79
ADHD 1,097 3 0.80 0.59 0.68
ODD 1,105 2 0.71 0.55 0.55
Early afternoon Total 1,045 6 0.87 0.61 0.78
ADHD 1,075 3 0.78 0.56 0.65
ODD 1,080 2 0.68 0.51 0.51
Late afternoon Total 1,051 6 0.87 0.58 0.79
ADHD 1,085 3 0.77 0.55 0.63
ODD 1,095 2 0.69 0.54 0.54
Evening Total 1,050 6 0.89 0.65 0.82
ADHD 1,082 3 0.81 0.63 0.67
ODD 1,090 2 0.72 0.56 0.56
Whole day Total 1,001 24 0.95 0.45 0.75
ADHD 1,043 12 0.90 0.45 0.74
ODD 1,056 8 0.91 0.63 0.77
PMRS 1,073 11 0.73 0.21 0.50
Teacher rating (DAYAS-T)
Morning, ﬁrst half Total 749 6 0.89 0.62 0.82
ADHD 762 3 0.80 0.56 0.69
ODD 764 2 0.74 0.58 0.58
Morning, second half Total 714 6 0.90 0.63 0.83
ADHD 730 3 0.81 0.57 0.73
ODD 740 2 0.76 0.61 0.61
Whole day Total 711 12 0.94 0.59 0.83
ADHD 728 6 0.89 0.57 0.77
ODD 736 4 0.88 0.73 0.75
PMRS 732 9 0.81 0.44 0.60
Parent and teacher rating (DAYAS-P ? T)
Whole day Total 594 36 0.95 0.42 0.69
ADHD 632 18 0.90 0.40 0.69
ODD 649 12 0.89 0.50 0.71
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123Convergent and divergent validity was assessed by
correlating DAYAS scores with parent ratings on the SDQ
in the OBSEER study (Table 4). As expected, DAYAS
ADHD and ODD ratings had the highest correlations with
the SDQ ratings of hyperactivity and conduct problems;
correlations with pro-social behaviour, peers and emo-
tional problems were substantially lower.
Discussion
We analysed data from a proof-of-concept study, and two
observational trials, the OBSEER Equasym XL
 study,
and a study of Medikinet
 retard, to show that the DAYAS
rating scale is a reliable and practical tool for assessing
ADHD and ODD symptoms across the day in real-world
settings.
Analyses of data from the proof-of-concept study show
that correlations between weekly and daily ratings of
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Fig. 1 DAYAS-P and DAYAS-T ratings in the combined sample.
Cases with missing values are excluded. Black and grey horizontal
bars represent the means with 95% conﬁdence intervals across all
daily ADHD (black) and ODD (grey) ratings, respectively. ADHD
attention deﬁcit hyperactivity disorder, ODD oppositional deﬁant
disorder
Table 3 Pearson correlations
between DAYAS externalising
symptom scores and FBB-
ADHD symptoms and
impairment ratings at baseline
in the OBSEER study
DAYAS Day Proﬁle of ADHD
Symptoms, FBB-ADHD
Fremdbeurteilungsbogen fu ¨r
hyperkinetische Sto ¨rungen
DAYAS score FBB-ADHD
symptoms total
parent score
FBB-ADHD
impairment parent
score
FBB-ADHD
symptoms total
teacher score
FBB-ADHD
impairment
teacher score
Early morning (parent) 0.42 0.32 0.23 0.14
School morning ﬁrst half (teacher) 0.37 0.30 0.76 0.69
School morning second half
(teacher)
0.39 0.29 0.82 0.74
Early afternoon (parent) 0.68 0.55 0.35 0.33
Late afternoon (parent) 0.63 0.48 0.30 0.24
Evening (parent) 0.48 0.37 0.18 0.12
Table 4 Pearson correlations of DAYAS-P and DAYAS-T externalising subscale ratings with SDQ subscale and total scores from the OBSEER
study
DAYAS SDQ
Time (assessor) Subscale Pro-social Peer Hyperactivity Conduct Emotion Total
Early morning (parent) ADHD -0.22 0.19 0.33 0.33 0.02 0.26
ODD -0.33 0.27 0.32 0.54 0.09 0.36
School morning ﬁrst half (teacher) ADHD -0.13 0.17 0.29 0.26 -0.12 0.18
ODD -0.25 0.27 0.24 0.37 -0.09 0.22
School morning second half (teacher) ADHD -0.10 0.13 0.34 0.31 -0.10 0.22
ODD -0.23 0.25 0.22 0.39 -0.08 0.22
Afternoon (parent) ADHD -0.22 0.20 0.57 0.44 0.12 0.43
ODD -0.35 0.27 0.41 0.63 0.14 0.44
Late afternoon (parent) ADHD -0.20 0.19 0.52 0.44 0.11 0.41
ODD -0.32 0.26 0.40 0.62 0.13 0.44
Evening (parent) ADHD -0.17 0.20 0.37 0.38 0.12 0.36
ODD -0.30 0.25 0.34 0.55 0.15 0.40
ADHD attention deﬁcit hyperactivity disorder, DAYAS Day Proﬁle of ADHD Symptoms, ODD, oppositional deﬁant disorder, SDQ Strengths and
Difﬁculties Questionnaire
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123externalising symptoms were sufﬁciently high enough to
indicate that weekly ratings can be substituted for daily
ratings. This may help to reduce the burden of assessments
on parents, teachers and healthcare professionals. It should
be noted, however, that the same-week correlations may
overestimate the true correlation, as the rating of each
single day may have increased the correspondence with the
weekly rating. However, in contrast, correlation values
between Week 1 and Week 2 may underestimate the true
correlation of the test, as behaviour may have changed over
the 2 weeks.
DAYAS rated weekly (including DAYAS-P and DA-
YAS-T for both externalising symptoms and potentially
medication-related symptoms) has satisfactory reliability,
as assessed by internal consistency or test–retest stability.
The high correlations of the externalising symptoms ratings
at different periods during the day with a total score across
all periods indicate that the ratings of the different daily
periods were quite homogenous; patients with a high rating
in the morning had a high rating in the evening and,
therefore, had a consistent contribution to the total scores.
While convergent validity was seen between DAYAS
externalising symptoms ratings and the FBB-ODD, FBB-
ADHD and the SDQ subscales hyperactivity and conduct
problems, substantially lower correlations for the subscales
pro-social behaviour, peers and emotional problems are
indicative of the divergent validity of the DAYAS scores.
DAYAS ADHD ratings accounted for 53% (parents) and
70% (teachers) of the ratings of ADHD according to DSM-
IV and ICD-10, which demonstrates a high convergent
validity. We believe these ﬁndings demonstrate the use-
fulness of DAYAS as a screening instrument and validate it
for use in ADHD. Moreover, two observational studies, the
OBSEER study [6] and the Medikinet
 retard observa-
tional study [7], and one randomized controlled trial [10]
demonstrate that changes in ADHD symptoms and ODD
symptoms during the switch of medication can be detected
with DAYAS. Thus, the sensitivity of the DAYAS scale to
change was also demonstrated. Therefore, we believe that
DAYAS is a helpful tool for clinical practice and research
to detect ADHD and ODD symptoms at different periods
during the day and to detect changes in ADHD/ODD
symptoms at different periods across the days. This may be
helpful in optimising medication effects across the day.
The potentially medication-related symptoms part of
both DAYAS-P and DAYAS-T has a good internal con-
sistency, despite the fact that the symptoms considered on
this scale were heterogeneous. This suggests that this scale
can be used to assess reliably the most frequently observed
side effects of ADHD medication. In addition to being
caused by ADHD medication, such symptoms can also be
comorbid symptoms of ADHD itself. Thus, an assessment
prior to starting medication may be useful for disentangling
side effects from comorbidity. DAYAS enables a simple
assessment of these symptoms using both parent and tea-
cher ratings.
In conclusion, these analyses show that DAYAS has
satisfactory reliability and validity, is sensitive towards
change, and, with the option of rating weekly instead of
daily, is feasible in routine care.
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